[{"orgOrder":0,"company":"Labcorp","sponsor":"NovelMed Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"NM8074","moa":"CFB","graph1":"Undisclosed","graph2":"Phase I","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"6","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Labcorp \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Undisclosed"},{"orgOrder":0,"company":"Labcorp","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"7","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"EpimAb Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"EMB-01","moa":"Epidermal growth factor receptor erbB1 | Hepatocyte growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"7","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"7","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Linafexor","moa":"FXR","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"8","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Labcorp \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Amgen Inc"},{"orgOrder":0,"company":"Labcorp","sponsor":"Nuance Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ensifentrine","moa":"Phosphodiesterase 3 | Phosphodiesterase 4","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"10","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Aurinia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Voclosporin","moa":"Serine\/threonine protein phosphatase 2B catalytic subunit, alpha isoform","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin||SLC40A1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"8","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin||SLC40A1","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"8","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Cellivery","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"iCP-NI","moa":"TNF-alpha receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"6","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GEH121224","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Labcorp \/ LabCorp","highestDevelopmentStatusID":"6","companyTruncated":"Labcorp \/ LabCorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Presage Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Labcorp","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Labcorp \/ Labcorp","highestDevelopmentStatusID":"5","companyTruncated":"Labcorp \/ Labcorp"},{"orgOrder":0,"company":"Labcorp","sponsor":"Xcell Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Labcorp \/ Xcell Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Labcorp \/ Xcell Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by Labcorp

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : The FDA has approved its nAbCyte Anti-AAVRh74var HB-FE Assay, a companion diagnostic to determine patient eligibility for treatment with Beqvez (fidanacogene elaparvovec).

                          Product Name : Beqvez

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          April 29, 2024

                          Lead Product(s) : Fidanacogene elaparvovec

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Voclosporin is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lupus Nephritis.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          July 27, 2023

                          Lead Product(s) : Voclosporin

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase III

                          Recipient : Aurinia Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Ensifentrine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 24, 2023

                          Lead Product(s) : Ensifentrine

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Recipient : Nuance Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : ICP-NI is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          February 23, 2023

                          Lead Product(s) : iCP-NI

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : Cellivery

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : NM8074 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          December 08, 2022

                          Lead Product(s) : NM8074

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Recipient : NovelMed Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : GEH121224 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 02, 2022

                          Lead Product(s) : GEH121224

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : GE Healthcare

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Linafexor is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 24, 2022

                          Lead Product(s) : Linafexor

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Phase II

                          Recipient : Cascade Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : EMB-01 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          August 12, 2022

                          Lead Product(s) : EMB-01

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : EpimAb Biotherapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Through the collaboration, Labcorp and Xcellbio will work on a series of projects focused on improving the safety and efficacy of cell and gene therapies (CGTs). s. The projects included in the collaboration will use Xcellbio’s AVATAR incubator system ...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 19, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Xcell Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          10

                          Luxepack
                          Not Confirmed
                          Luxepack
                          Not Confirmed

                          Details : Infigratinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 03, 2022

                          Lead Product(s) : Infigratinib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Helsinn Advanced Synthesis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank